Alison Bryant

Biography for Alison Bryant

Alison Bryant began at FierceVaccines in 2012. She has covered local politics, growth and development and breaking news in Maryland and Vermont. Her work has been published in The Washington Post, The Burlington Free Press and The Gazette. In her free time, Bryant enjoys reading, creative writing and yoga. She's based in Washington, D.C. and can be reached at abryant@fiercemarkets.com. Follow @AlisonBFierce on Twitter.

Articles by Alison Bryant

GE, iBio unite on plant-based production of vaccines and biologics

GE Healthcare and iBio ($IBIO) will partner to commercialize plant-based technologies for the manufacturing of biopharmaceuticals and vaccines.

FDA wags finger at Sanofi for no-nos at vaccine plants

The FDA admonished Sanofi Pasteur on more than two dozen counts for "objectionable" conditions in two plants in Canada and France, according to a warning letter dated July 12 and made public July 24.

Vaxil BioTherapeutics debuts on Tel Aviv Stock Exchange

Vaxil BioTherapeutics made its debut on the Tel Aviv Stock Exchange through a merger with Sheldonco.

Sanofi vaccine combats most viral causes of dengue

Sanofi Pasteur took a big leap forward Wednesday, announcing that its tetravalent dengue fever vaccine candidate demonstrated proof of efficacy against dengue in a trial conducted in Thailand.

UPDATED: Researchers hope to turn white blood cells into a vaccine

Researchers at Northwestern Brain Tumor Institute are working to figure out whether a vaccine made from a patient's own white blood cells can be used to attack cancers by slowing the growth of tumors.

Medicago completes rapid-fire flu vaccine production

Medicago successfully completed an attempt to quickly deliver H1N1 VLP influenza vaccine candidates, slinging at least 10 million doses in one month.

Sanofi, Pitt team to develop universal seasonal flu vaccine

Sanofi Pasteur will join University of Pittsburgh scientists to develop a vaccine for all strains of seasonal influenza that will take as little as four months to produce.

Animal model replicates human response to HIV

By transplanting elements of the human immune system into an immunodeficient mouse, researchers at Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard inched closer to reducing the time and cost required to test HIV candidate vaccines.

Galena stock jumps with NeuVax patent

Galena Bipharma's stock jumped a cool 35% when the company received a patent granting its breast cancer vaccine exclusivity until 2028.

Oral vax rides on advanced microparticles

Researchers in the U.S. and China have worked together to develop microparticles that carry vaccine nanoparticles through the stomach and release them in the large intestine when the pH levels are on point.